San Diego-based Tandem launched Mobi, the world’s smallest, durable automated insulin delivery (AID) system in the U.S. this year. It received FDA clearance for people with diabetes ages six and up in July 2023. The system pairs with both the Dexcom G6 and G7 CGMs, offering multiple options to patients. Tandem also plans to integrate Mobi (and its t:slim X2 pump) with the Abbott FreeStyle Libre 3 in the future.
Tandem shared a survey on user satisfaction and wearability, finding that 86% of patients reported that they were satisfied or very satisfied with Mobi regardless of prior therapy and agreed that Mobi helps improve their quality of life. The company presented its data at the American Diabetes Association Scientific Sessions in Orlando, Florida.
“These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with diabetes by demonstrating that Tandem Mobi not only meets, but exceeds user expectations,” said Dr. Jordan Pinsker, chief medical officer at Tandem Diabetes Care. “We are proud to share these results at ADA and will continue to innovate to provide the diabetes community with choice and improved quality of life.”
A look at the Tandem data
In a six-week limited launch survey, the company heard from early users who previously used multiple daily injections (MDI), other insulin pumps (tubed and tubeless) or previous tandem pumps. They exhibited high satisfaction with the wearability features of Mobi combined with the Control-IQ algorithm.
Mobi’s size enables users to wear it almost anywhere with greater discretion, comfort and flexibility. Control-IQ technology, meanwhile, predicts and helps prevent highs and lows.
For prior pump users, 78% said Mobi reduces diabetes management burden and 88% say it’s easy to use, while 80% said it delivers more freedom in their lives.
Other data shared at ADA included Mobi users and highlighted improved time in range with no increase in time spent below range. Younger users highlighted form factor, portability, discreteness and wearability as paramount to satisfaction and ongoing use.
Tandem highlighted a number of features contributing to these satisfaction drivers, including a 30-unit minimum fill to reduce insulin waste for those with low insulin requirements. Mobi’s physical on-pump quick bolus button enables simple, discreet bolusing with programming in grams or unit increments.
On-body wear features a lightweight adhesive sleeve and five-inch tubing, while users can control Mobi from their personal iPhone.
